Ascendis Pharma A (ASND)
Ascendis Pharma develops rare disease treatments based on its TransCon technology, including YORVIPATH and SKYTROFA. It last closed at $271.19 on Nov 17, down 0.20% on the day. ASND reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 15 analysts is $318.47 (+17.4% from the last close), with a high of $356.00 and a low of $273.00. Analyst consensus is Strong Buy, based on the latest ratings from 15 firms (14 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ASND, 0% of them bullish and 100% bearish. In the past 30 days there were 8 dark pool prints totaling $9.8M, the largest $2.5M.
Key Stats
Last 12 monthsNot reported for this period.
From ASND's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 11). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 15 analysts who set a price target on ASND in the past 90 days. The average target is $318.47, with a high of $356.00 and a low of $273.00, compared with the last close of $271.19.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Barclays | Target raised | Buy | $329 → $341 |
| Nov 13 | UBS | Target raised | Buy | $269 → $315 |
| Nov 13 | TD Cowen | Target raised | Buy | $341 → $352 |
| Nov 13 | Evercore ISI Group | Maintained | Buy | $356 |
| Nov 13 | Canaccord Genuity | Maintained | Hold | $274 |
Technical Analysis
The stock is 6% above its 20 day and 10% above its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 69), near overbought. The nearest support is the Pivot at $267.96, and the nearest resistance the swing high (Jun 25) at $271.89.
| RSI (14) | 68.96 | Strong, overbought above 70 | Neutral |
| MACD | 8.52 | Above its signal line | Bullish |
| Stochastic | 82.5 | Near the top of its range | Overbought |
| ADX (14) | 39.5 | Trending up | |
| Williams %R | -24.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 120.2 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +8.4% | Change over 10 sessions | Bullish |
| ATR (14) | $7.34 | Typical daily range, 2.7% of price |
| RSI (14) | 59.79 | Middle of its range | Neutral |
| MACD | 6.17 | Above its signal line | Bullish |
| Stochastic | 84.2 | Near the top of its range | Overbought |
| ADX (14) | 14.9 | No clear trend | |
| Williams %R | -12.5 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 116.1 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +2.9% | Change over 10 sessions | Bullish |
| ATR (14) | $18.19 | Typical daily range, 6.7% of price |
What happened before
See how ASND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ASND has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in ASND in the last 90 days.
Dark Pool
30DASND Institutional Ownership
Full report →- ▲222 buying vs 145 selling
- ▲Shares held by funds +2.1%
- ▲Funds holding +34
- ▼Superinvestors: 1 added, 3 cut
- ▼Put/call 0.14 to 0.15
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 350 | 316 | +10.8% |
| In funds' top 10 | 16 | 13 | +23.1% |
| Held by funds | – | – | – |
| New / increased | 83 / 139 | 296 / 7 | −26.7% |
| Reduced / sold out | 97 / 48 | 4 / 267 | −46.5% |
| Put/call ratio | 0.15 | 0.14 | +7.2% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ASND is in one of them and how their past ASND trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ASND in an article yet. Here's the latest on the wider market.
ASND Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gary PalmerR · AL | Sell | $1K – $15K | Oct 5, 2018 | Nov 7, 2018 | 33 d |
| Gary PalmerR · AL | Buy | $1K – $15K | Aug 6, 2018 | Sep 29, 2018 | 54 d |
| Gary PalmerR · AL | Buy | $1K – $15K | Jul 12, 2018 | Sep 29, 2018 | 79 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ascendis Pharma A
Ascendis Pharma is a biopharmaceutical company based in Hellerup, Denmark. It develops medicines built on its TransCon technology, with a focus on rare endocrine conditions. Its approved products are YORVIPATH, for adults with hypoparathyroidism, and SKYTROFA, for people with growth hormone deficiency. The company also has product candidates in development for other growth disorders and in oncology, and it works with partners in Japan and China. Its customers are patients and the healthcare providers who prescribe its treatments.
- Headquarters
- Hellerup
- Founded
- 2007
- Website
- ascendispharma.com ↗




